{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:04:54Z","timestamp":1789617894939,"version":"build-2803163510"},"reference-count":253,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Natural Sciences Foundations of China","award":["No. 81972838"],"award-info":[{"award-number":["No. 81972838"]}]},{"name":"the National Natural Sciences Foundations of China","award":["No.82272722"],"award-info":[{"award-number":["No.82272722"]}]},{"name":"the National Natural Sciences Foundations of China","award":["No. 82504122"],"award-info":[{"award-number":["No. 82504122"]}]},{"DOI":"10.13039\/501100019092","name":"Science Fund for Distinguished Young Scholars of Hunan Province","doi-asserted-by":"publisher","award":["No: 2024JJ6592"],"award-info":[{"award-number":["No: 2024JJ6592"]}],"id":[{"id":"10.13039\/501100019092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nasopharyngeal carcinoma (NPC) is a distinctive epithelial malignancy characterized by marked geographic and ethnic clustering, with the greatest burden concentrated in East and Southeast Asia despite declining age-standardized incidence and mortality rates in many regions. NPC arises from a complex interaction among persistent Epstein\u2013Barr virus (EBV) infection, inherited susceptibility, and environmental exposures. Among these factors, EBV plays a central role in endemic NPC through latent gene products, particularly latent membrane protein 1 (LMP1), latent membrane protein 2A (LMP2A), and Epstein\u2013Barr nuclear antigen 1 (EBNA1), which sustain oncogenic signaling, remodel the tumor microenvironment, and reinforce malignant progression. Clinically, NPC is often diagnosed at a locoregionally advanced stage because of its deep anatomical location and nonspecific early symptoms, making accurate detection, risk stratification, and treatment selection particularly important. Although previous reviews have addressed individual aspects of NPC biology or management, an integrated framework linking epidemiological determinants, viral oncogenesis, host molecular dysregulation, and therapeutic evolution remains needed. This review therefore synthesizes current evidence on NPC epidemiology, risk factors, EBV-associated molecular mechanisms, major signaling pathways and their crosstalk, genetic and epigenetic alterations, clinical features, diagnosis, staging, and management. Particular emphasis is placed on the clinical roles and limitations of plasma EBV DNA, the distinction between established standards and investigational strategies, and emerging molecular and immune-based therapies. By linking mechanistic insights with their clinical and translational implications, this review provides a biologically informed framework for understanding NPC and highlights priorities for biomarker standardization, risk-adapted treatment, and future therapeutic development.<\/jats:p>","DOI":"10.1186\/s43556-026-00590-6","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:46:12Z","timestamp":1789616772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nasopharyngeal carcinoma: epidemiology, risk factors, signaling pathways, clinical features, diagnosis, and management"],"prefix":"10.1186","volume":"7","author":[{"given":"Yangbingyu","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songqing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"10192","key":"590_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(19)30956-0.","journal-title":"Lancet"},{"issue":"1","key":"590_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12105-022-01449-2","volume":"16","author":"C Badoual","year":"2022","unstructured":"Badoual C. Update from the 5th edition of the World Health Organization classification of head and neck tumors: oropharynx and nasopharynx. Head Neck Pathol. 2022;16(1):19\u201330. https:\/\/doi.org\/10.1007\/s12105-022-01449-2.","journal-title":"Head Neck Pathol"},{"issue":"2","key":"590_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00432-023-05547-8","volume":"150","author":"JS van Velsen","year":"2024","unstructured":"van Velsen JS, van der Vegt B, Plaat BEC, Langendijk JA, Epskamp-Kuijpers C, van Dijk BAC, et al. Nasopharyngeal carcinoma: nationwide trends in subtype-specific incidence and survival over 3 decades in a non-endemic area. J Cancer Res Clin Oncol. 2024;150(2):49. https:\/\/doi.org\/10.1007\/s00432-023-05547-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"590_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.2340\/1651-226x.2024.40499","volume":"63","author":"E Schiess","year":"2024","unstructured":"Schiess E, Jensen KH, Kristensen MH, Johansen J, Eriksen JG, Maare C, et al. Epidemiology and treatment outcome of nasopharyngeal carcinoma in a low-incidence population - a DAHANCA analysis in Denmark 2000\u20132018. Acta Oncol. 2024;63:850\u20137. https:\/\/doi.org\/10.2340\/1651-226x.2024.40499.","journal-title":"Acta Oncol"},{"key":"590_CR5","doi-asserted-by":"publisher","unstructured":"Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732). https:\/\/doi.org\/10.1098\/rstb.2016.0270.","DOI":"10.1098\/rstb.2016.0270"},{"issue":"2","key":"590_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajhg.2009.07.007","volume":"85","author":"KP Tse","year":"2009","unstructured":"Tse KP, Su WH, Chang KP, Tsang NM, Yu CJ, Tang P, et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet. 2009;85(2):194\u2013203. https:\/\/doi.org\/10.1016\/j.ajhg.2009.07.007.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"590_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/ng.601","volume":"42","author":"JX Bei","year":"2010","unstructured":"Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42(7):599\u2013603. https:\/\/doi.org\/10.1038\/ng.601.","journal-title":"Nat Genet"},{"issue":"2","key":"590_CR8","first-page":"956","volume":"46","author":"MC Yu","year":"1986","unstructured":"Yu MC, Ho JH, Lai SH, Henderson BE. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res. 1986;46(2):956\u201361.","journal-title":"Cancer Res"},{"issue":"3","key":"590_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/ije\/dyab060","volume":"50","author":"JH Lin","year":"2021","unstructured":"Lin JH, Wen CP, Jiang CQ, Yuan JM, Chen CJ, Ho SY, et al. Smoking and nasopharyngeal cancer: individual data meta-analysis of six prospective studies on 334 935 men. Int J Epidemiol. 2021;50(3):975\u201386. https:\/\/doi.org\/10.1093\/ije\/dyab060.","journal-title":"Int J Epidemiol"},{"issue":"23","key":"590_CR10","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/jnci\/94.23.1780","volume":"94","author":"A Hildesheim","year":"2002","unstructured":"Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 2002;94(23):1780\u20139. https:\/\/doi.org\/10.1093\/jnci\/94.23.1780.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"590_CR11","doi-asserted-by":"publisher","first-page":"e1003103","DOI":"10.1371\/journal.pgen.1003103","volume":"8","author":"M Tang","year":"2012","unstructured":"Tang M, Lautenberger JA, Gao X, Sezgin E, Hendrickson SL, Troyer JL, et al. The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove. PLoS Genet. 2012;8(11):e1003103. https:\/\/doi.org\/10.1371\/journal.pgen.1003103.","journal-title":"PLoS Genet"},{"issue":"9","key":"590_CR12","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/jn\/nxz095","volume":"149","author":"D Barrett","year":"2019","unstructured":"Barrett D, Ploner A, Chang ET, Liu Z, Zhang CX, Liu Q, et al. Past and recent salted fish and preserved food intakes are weakly associated with nasopharyngeal carcinoma risk in adults in Southern China. J Nutr. 2019;149(9):1596\u2013605. https:\/\/doi.org\/10.1093\/jn\/nxz095.","journal-title":"J Nutr"},{"issue":"12","key":"590_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/aje\/kwx018","volume":"185","author":"ET Chang","year":"2017","unstructured":"Chang ET, Liu Z, Hildesheim A, Liu Q, Cai Y, Zhang Z, et al. Active and passive smoking and risk of nasopharyngeal carcinoma: a population-based case-control study in Southern China. Am J Epidemiol. 2017;185(12):1272\u201380. https:\/\/doi.org\/10.1093\/aje\/kwx018.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"590_CR14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/ng.3006","volume":"46","author":"DC Lin","year":"2014","unstructured":"Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46(8):866\u201371. https:\/\/doi.org\/10.1038\/ng.3006.","journal-title":"Nat Genet"},{"key":"590_CR15","doi-asserted-by":"publisher","first-page":"104357","DOI":"10.1016\/j.ebiom.2022.104357","volume":"86","author":"L-Y Chow","year":"2022","unstructured":"Chow L-Y, Chung D-S, Tao L, Chan KF, Tung SY, Cheong Ngan RK, et al. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma. EBioMedicine. 2022;86:104357. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104357.","journal-title":"EBioMedicine"},{"issue":"8","key":"590_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41419-023-06028-z","volume":"14","author":"L Liu","year":"2023","unstructured":"Liu L, Deng P, Liu S, Hong JH, Xiao R, Guan P, et al. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma. Cell Death Dis. 2023;14(8):513. https:\/\/doi.org\/10.1038\/s41419-023-06028-z.","journal-title":"Cell Death Dis"},{"key":"590_CR17","doi-asserted-by":"publisher","first-page":"105057","DOI":"10.1016\/j.ebiom.2024.105057","volume":"102","author":"H Mizokami","year":"2024","unstructured":"Mizokami H, Okabe A, Choudhary R, Mima M, Saeda K, Fukuyo M, et al. Enhancer infestation drives tumorigenic activation of inactive B compartment in Epstein-Barr virus-positive nasopharyngeal carcinoma. EBioMedicine. 2024;102:105057. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105057.","journal-title":"EBioMedicine"},{"issue":"6","key":"590_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/annonc\/mdz106","volume":"30","author":"AD King","year":"2019","unstructured":"King AD, Woo JKS, Ai QY, Chan JSM, Lam WKJ, Tse IOL, et al. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. Ann Oncol. 2019;30(6):977\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdz106.","journal-title":"Ann Oncol"},{"issue":"11","key":"590_CR19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","volume":"41","author":"LL Tang","year":"2021","unstructured":"Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 2021;41(11):1195\u2013227. https:\/\/doi.org\/10.1002\/cac2.12218.","journal-title":"Cancer Commun (Lond)"},{"issue":"22","key":"590_CR20","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/jco.22.00327","volume":"40","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol. 2022;40(22):2420\u20135. https:\/\/doi.org\/10.1200\/jco.22.00327.","journal-title":"J Clin Oncol"},{"issue":"12","key":"590_CR21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","volume":"8","author":"J Miao","year":"2022","unstructured":"Miao J, Wang L, Tan SH, Li JG, Yi J, Ong EHW, et al. Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol. 2022;8(12):1776\u201385. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4656.","journal-title":"JAMA Oncol"},{"issue":"20","key":"590_CR22","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA. 2023;330(20):1961\u201370. https:\/\/doi.org\/10.1001\/jama.2023.20181.","journal-title":"JAMA"},{"issue":"3","key":"590_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"590_CR24","doi-asserted-by":"publisher","first-page":"e49968","DOI":"10.2196\/49968","volume":"9","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Rumgay H, Li M, Cao S, Chen W. Nasopharyngeal cancer incidence and mortality in 185 countries in 2020 and the projected burden in 2040: population-based global epidemiological profiling. JMIR Public Health Surveill. 2023;9:e49968. https:\/\/doi.org\/10.2196\/49968.","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"590_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40880-017-0257-9","volume":"36","author":"KR Wei","year":"2017","unstructured":"Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):90. https:\/\/doi.org\/10.1186\/s40880-017-0257-9.","journal-title":"Chin J Cancer"},{"key":"590_CR26","doi-asserted-by":"publisher","unstructured":"Zhang R, He Y, Wei B, Lu Y, Zhang J, Zhang N, et al. Nasopharyngeal carcinoma burden and its attributable risk factors in China: estimates and forecasts from 1990 to 2050. Int J Environ Res Public Health. 2023;20(4). https:\/\/doi.org\/10.3390\/ijerph20042926.","DOI":"10.3390\/ijerph20042926"},{"issue":"5","key":"590_CR27","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/ijc.30525","volume":"140","author":"Y Rottenberg","year":"2017","unstructured":"Rottenberg Y, Levine H, Keinan-Boker L, Derazne E, Leiba A, Kark JD. Risk of nasopharyngeal carcinoma penetrates across immigrant generations: a migrant cohort study of 2.3 million Jewish Israeli adolescents. Int J Cancer. 2017;140(5):1060\u20137. https:\/\/doi.org\/10.1002\/ijc.30525.","journal-title":"Int J Cancer"},{"issue":"1","key":"590_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2016.01.040","volume":"374","author":"LL Tang","year":"2016","unstructured":"Tang LL, Chen WQ, Xue WQ, He YQ, Zheng RS, Zeng YX, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer Lett. 2016;374(1):22\u201330. https:\/\/doi.org\/10.1016\/j.canlet.2016.01.040.","journal-title":"Cancer Lett"},{"issue":"2","key":"590_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2012.01.007","volume":"22","author":"A Hildesheim","year":"2012","unstructured":"Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000\u20132011: Rosetta stone for NPC: genetics, viral infection, and other environmental factors. Semin Cancer Biol. 2012;22(2):107\u201316. https:\/\/doi.org\/10.1016\/j.semcancer.2012.01.007.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"590_CR30","first-page":"1355","volume":"146","author":"R Pathmanathan","year":"1995","unstructured":"Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol. 1995;146(6):1355\u201367.","journal-title":"Am J Pathol"},{"issue":"2","key":"590_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.semcancer.2011.12.002","volume":"22","author":"L Frappier","year":"2012","unstructured":"Frappier L. Role of EBNA1 in NPC tumourigenesis. Semin Cancer Biol. 2012;22(2):154\u201361. https:\/\/doi.org\/10.1016\/j.semcancer.2011.12.002.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"590_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/v5010226","volume":"5","author":"D Westhoff Smith","year":"2013","unstructured":"Westhoff Smith D, Sugden B. Potential cellular functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr virus. Viruses. 2013;5(1):226\u201340. https:\/\/doi.org\/10.3390\/v5010226.","journal-title":"Viruses"},{"issue":"23","key":"590_CR33","doi-asserted-by":"publisher","first-page":"13020","DOI":"10.1128\/jvi.01606-13","volume":"87","author":"TL Hodin","year":"2013","unstructured":"Hodin TL, Najrana T, Yates JL. Efficient replication of Epstein-Barr virus-derived plasmids requires tethering by EBNA1 to host chromosomes. J Virol. 2013;87(23):13020\u20138. https:\/\/doi.org\/10.1128\/jvi.01606-13.","journal-title":"J Virol"},{"issue":"5","key":"590_CR34","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1128\/jvi.66.5.2689-2697.1992","volume":"66","author":"L Brooks","year":"1992","unstructured":"Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol. 1992;66(5):2689\u201397. https:\/\/doi.org\/10.1128\/jvi.66.5.2689-2697.1992.","journal-title":"J Virol"},{"issue":"1","key":"590_CR35","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1038\/s41467-021-24348-6","volume":"12","author":"JP Bruce","year":"2021","unstructured":"Bruce JP, To KF, Lui VWY, Chung GTY, Chan YY, Tsang CM, et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-\u03baB activation and immune escape. Nat Commun. 2021;12(1):4193. https:\/\/doi.org\/10.1038\/s41467-021-24348-6.","journal-title":"Nat Commun"},{"issue":"24","key":"590_CR36","doi-asserted-by":"publisher","first-page":"e71183","DOI":"10.1096\/fj.202502319RR","volume":"39","author":"S Zhang","year":"2025","unstructured":"Zhang S, Tang J, Yuan F, Yuan H, Wu S. EBV-LMP1 promotes the progression of nasopharyngeal carcinoma via TNC-mediated activation of PI3K\/Akt pathway. FASEB J. 2025;39(24):e71183. https:\/\/doi.org\/10.1096\/fj.202502319RR.","journal-title":"FASEB J"},{"issue":"13","key":"590_CR37","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1002\/cam4.2506","volume":"8","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Yu X, Zhou Z, Li B, Peng J, Wu X, et al. LMP1-positive extracellular vesicles promote radioresistance in nasopharyngeal carcinoma cells through P38 MAPK signaling. Cancer Med. 2019;8(13):6082\u201394. https:\/\/doi.org\/10.1002\/cam4.2506.","journal-title":"Cancer Med"},{"issue":"34","key":"590_CR38","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1038\/onc.2014.380","volume":"34","author":"X Zhou","year":"2015","unstructured":"Zhou X, Matskova L, Rathje LS, Xiao X, Gish G, Werner M, et al. SYK interaction with ITG\u03b24 suppressed by Epstein-Barr virus LMP2A modulates migration and invasion of nasopharyngeal carcinoma cells. Oncogene. 2015;34(34):4491\u20139. https:\/\/doi.org\/10.1038\/onc.2014.380.","journal-title":"Oncogene"},{"key":"590_CR39","doi-asserted-by":"publisher","unstructured":"Hu J, Xin F, Liu W, Gong Z, Zhang Y, Liu S. Downregulation of KLF5 by EBER1 via the ERK signaling pathway in EBV-positive nasopharyngeal carcinoma cells: implications for latent EBV infection. J Gen Virol. 2024;105(5). https:\/\/doi.org\/10.1099\/jgv.0.001988.","DOI":"10.1099\/jgv.0.001988"},{"issue":"1","key":"590_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2015.02.037","volume":"361","author":"Y Duan","year":"2015","unstructured":"Duan Y, Li Z, Cheng S, Chen Y, Zhang L, He J, et al. Nasopharyngeal carcinoma progression is mediated by EBER-triggered inflammation via the RIG-I pathway. Cancer Lett. 2015;361(1):67\u201374. https:\/\/doi.org\/10.1016\/j.canlet.2015.02.037.","journal-title":"Cancer Lett"},{"issue":"6","key":"590_CR41","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.bbadis.2019.01.015","volume":"1865","author":"S Cheng","year":"2019","unstructured":"Cheng S, Li Z, He J, Fu S, Duan Y, Zhou Q, et al. Epstein-Barr virus noncoding RNAs from the extracellular vesicles of nasopharyngeal carcinoma (NPC) cells promote angiogenesis via TLR3\/RIG-I-mediated VCAM-1 expression. Biochim Biophys Acta Mol Basis Dis. 2019;1865(6):1201\u201313. https:\/\/doi.org\/10.1016\/j.bbadis.2019.01.015.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"590_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.canlet.2019.01.022","volume":"447","author":"YJ Xu","year":"2019","unstructured":"Xu YJ, Zhou R, Zong JF, Lin WS, Tong S, Guo QJ, et al. Epstein-Barr virus-coded miR-BART13 promotes nasopharyngeal carcinoma cell growth and metastasis via targeting of the NKIRAS2\/NF-\u03baB pathway. Cancer Lett. 2019;447:33\u201340. https:\/\/doi.org\/10.1016\/j.canlet.2019.01.022.","journal-title":"Cancer Lett"},{"issue":"1","key":"590_CR43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13046-018-0953-6","volume":"37","author":"C Lin","year":"2018","unstructured":"Lin C, Zong J, Lin W, Wang M, Xu Y, Zhou R, et al. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-\u03baB and Erk1\/2 pathways. J Exp Clin Cancer Res. 2018;37(1):283. https:\/\/doi.org\/10.1186\/s13046-018-0953-6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"590_CR44","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41419-022-05107-x","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang T, Chen Z, Deng J, Xu K, Che D, Lin J, et al. Epstein-Barr virus-encoded microRNA BART22 serves as novel biomarkers and drives malignant transformation of nasopharyngeal carcinoma. Cell Death Dis. 2022;13(7):664. https:\/\/doi.org\/10.1038\/s41419-022-05107-x.","journal-title":"Cell Death Dis"},{"issue":"6","key":"590_CR45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1701717","volume":"377","author":"KCA Chan","year":"2017","unstructured":"Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):513\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1701717.","journal-title":"N Engl J Med"},{"issue":"1","key":"590_CR46","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1038\/s41467-021-25402-z","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou X, Cao SM, Cai YL, Zhang X, Zhang S, Feng GF, et al. A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma. Nat Commun. 2021;12(1):5189. https:\/\/doi.org\/10.1038\/s41467-021-25402-z.","journal-title":"Nat Commun"},{"issue":"1","key":"590_CR47","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s42003-020-01487-y","volume":"3","author":"L Ning","year":"2020","unstructured":"Ning L, Ko JM, Yu VZ, Ng HY, Chan CK, Tao L, et al. Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. Commun Biol. 2020;3(1):759. https:\/\/doi.org\/10.1038\/s42003-020-01487-y.","journal-title":"Commun Biol"},{"issue":"1","key":"590_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1084\/jem.20031680","volume":"200","author":"D Zernich","year":"2004","unstructured":"Zernich D, Purcell AW, Macdonald WA, Kjer-Nielsen L, Ely LK, Laham N, et al. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. J Exp Med. 2004;200(1):13\u201324. https:\/\/doi.org\/10.1084\/jem.20031680.","journal-title":"J Exp Med"},{"issue":"16","key":"590_CR49","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1093\/hmg\/ddw200","volume":"25","author":"Q Cui","year":"2016","unstructured":"Cui Q, Feng QS, Mo HY, Sun J, Xia YF, Zhang H, et al. An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma. Hum Mol Genet. 2016;25(16):3626\u201334. https:\/\/doi.org\/10.1093\/hmg\/ddw200.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"590_CR50","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/1055-9965.Epi-15-0144","volume":"25","author":"JX Bei","year":"2016","unstructured":"Bei JX, Su WH, Ng CC, Yu K, Chin YM, Lou PJ, et al. A GWAS meta-analysis and replication study identifies a novel locus within CLPTM1L\/TERT associated with nasopharyngeal carcinoma in individuals of Chinese ancestry. Cancer Epidemiol Biomarkers Prev. 2016;25(1):188\u201392. https:\/\/doi.org\/10.1158\/1055-9965.Epi-15-0144.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"590_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13059-025-03657-9","volume":"26","author":"TM Wang","year":"2025","unstructured":"Wang TM, Zhang WL, Xie JR, He YQ, Tang M, Xue WQ, et al. A genome-wide association study integrated with single-cell and bulk profiles uncovers susceptibility genes for nasopharyngeal carcinoma involved in tumorigenesis via regulation of T cells. Genome Biol. 2025;26(1):195. https:\/\/doi.org\/10.1186\/s13059-025-03657-9.","journal-title":"Genome Biol"},{"issue":"5","key":"590_CR52","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s00405-021-07210-9","volume":"279","author":"M Lian","year":"2022","unstructured":"Lian M. Salted fish and processed foods intake and nasopharyngeal carcinoma risk: a dose-response meta-analysis of observational studies. Eur Arch Otorhinolaryngol. 2022;279(5):2501\u20139. https:\/\/doi.org\/10.1007\/s00405-021-07210-9.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"18","key":"590_CR53","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jnci\/djs320","volume":"104","author":"FH Xu","year":"2012","unstructured":"Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst. 2012;104(18):1396\u2013410. https:\/\/doi.org\/10.1093\/jnci\/djs320.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"590_CR54","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cam4.2083","volume":"8","author":"T Hu","year":"2019","unstructured":"Hu T, Lin CY, Xie SH, Chen GH, Lu YQ, Ling W, et al. Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr virus: an analysis of a prospective study in southern China. Cancer Med. 2019;8(5):2561\u201371. https:\/\/doi.org\/10.1002\/cam4.2083.","journal-title":"Cancer Med"},{"issue":"5","key":"590_CR55","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/cam4.2832","volume":"9","author":"WL Hsu","year":"2020","unstructured":"Hsu WL, Chien YC, Huang YT, Yu KJ, Ko JY, Lin CY, et al. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: a mediation analysis. Cancer Med. 2020;9(5):1867\u201376. https:\/\/doi.org\/10.1002\/cam4.2832.","journal-title":"Cancer Med"},{"issue":"1","key":"590_CR56","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12885-018-4110-6","volume":"18","author":"Y Chen","year":"2018","unstructured":"Chen Y, Xu Y, Zhao W, Xiao X, Zhou X, Lin L, et al. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres. BMC Cancer. 2018;18(1):190. https:\/\/doi.org\/10.1186\/s12885-018-4110-6.","journal-title":"BMC Cancer"},{"issue":"6","key":"590_CR57","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/oem.57.6.376","volume":"57","author":"TL Vaughan","year":"2000","unstructured":"Vaughan TL, Stewart PA, Teschke K, Lynch CF, Swanson GM, Lyon JL, et al. Occupational exposure to formaldehyde and wood dust and nasopharyngeal carcinoma. Occup Environ Med. 2000;57(6):376\u201384. https:\/\/doi.org\/10.1136\/oem.57.6.376.","journal-title":"Occup Environ Med"},{"issue":"11","key":"590_CR58","first-page":"1145","volume":"10","author":"A Hildesheim","year":"2001","unstructured":"Hildesheim A, Dosemeci M, Chan CC, Chen CJ, Cheng YJ, Hsu MM, et al. Occupational exposure to wood, formaldehyde, and solvents and risk of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2001;10(11):1145\u201353.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"590_CR59","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2012.01.004","volume":"22","author":"CW Dawson","year":"2012","unstructured":"Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 2012;22(2):144\u201353. https:\/\/doi.org\/10.1016\/j.semcancer.2012.01.004.","journal-title":"Semin Cancer Biol"},{"key":"590_CR60","doi-asserted-by":"publisher","unstructured":"Kase K, Kondo S, Wakisaka N, Dochi H, Mizokami H, Kobayashi E, et al. Epstein-Barr virus LMP1 induces soluble PD-L1 in nasopharyngeal carcinoma. Microorganisms. 2021;9(3). https:\/\/doi.org\/10.3390\/microorganisms9030603.","DOI":"10.3390\/microorganisms9030603"},{"issue":"12","key":"590_CR61","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/cac2.12619","volume":"44","author":"F He","year":"2024","unstructured":"He F, Gong Y, Tao G, Zhang J, Wu Q, Tan Y, et al. Targeting the LMP1-ALIX axis in EBV(+) nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti-tumor immunity. Cancer Commun (Lond). 2024;44(12):1391\u2013413. https:\/\/doi.org\/10.1002\/cac2.12619.","journal-title":"Cancer Commun (Lond)"},{"issue":"7","key":"590_CR62","first-page":"1946","volume":"7","author":"T Yoshizaki","year":"2001","unstructured":"Yoshizaki T, Horikawa T, Qing-Chun R, Wakisaka N, Takeshita H, Sheen TS, et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res. 2001;7(7):1946\u201351.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"590_CR63","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/00005537-200405000-00012","volume":"114","author":"Q Ren","year":"2004","unstructured":"Ren Q, Sato H, Murono S, Furukawa M, Yoshizaki T. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope. 2004;114(5):855\u20139. https:\/\/doi.org\/10.1097\/00005537-200405000-00012.","journal-title":"Laryngoscope"},{"key":"590_CR64","doi-asserted-by":"publisher","unstructured":"Zhang J, Jia L, Lin W, Yip YL, Lo KW, Lau VMY, et al. Epstein-Barr virus-encoded latent membrane protein 1 upregulates glucose transporter 1 transcription via the mTORC1\/NF-\u03baB signaling pathways. J Virol. 2017;91(6). https:\/\/doi.org\/10.1128\/jvi.02168-16.","DOI":"10.1128\/jvi.02168-16"},{"issue":"9","key":"590_CR65","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1128\/jvi.01703-10","volume":"85","author":"CP Kung","year":"2011","unstructured":"Kung CP, Meckes DG Jr, Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J Virol. 2011;85(9):4399\u2013408. https:\/\/doi.org\/10.1128\/jvi.01703-10.","journal-title":"J Virol"},{"key":"590_CR66","doi-asserted-by":"publisher","unstructured":"Morris MA, Laverick L, Wei W, Davis AM, O'Neill S, Wood L, et al. The EBV-encoded oncoprotein, LMP1, induces an Epithelial-to-Mesenchymal Transition (EMT) via its CTAR1 domain through integrin-mediated ERK-MAPK signalling. Cancers (Basel). 2018;10(5). https:\/\/doi.org\/10.3390\/cancers10050130.","DOI":"10.3390\/cancers10050130"},{"key":"590_CR67","doi-asserted-by":"publisher","first-page":"1078504","DOI":"10.3389\/fcimb.2022.1078504","volume":"12","author":"Y Guo","year":"2023","unstructured":"Guo Y, Kamara S, Zhang J, Wen H, Zheng M, Liu Y, et al. EBV LMP1-C terminal binding affibody molecule downregulates MEK\/ERK\/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models. Front Cell Infect Microbiol. 2023;12:1078504. https:\/\/doi.org\/10.3389\/fcimb.2022.1078504.","journal-title":"Front Cell Infect Microbiol"},{"issue":"15","key":"590_CR68","doi-asserted-by":"publisher","first-page":"10084","DOI":"10.1073\/pnas.152059399","volume":"99","author":"CN Tsai","year":"2002","unstructured":"Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A. 2002;99(15):10084\u20139. https:\/\/doi.org\/10.1073\/pnas.152059399.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"590_CR69","doi-asserted-by":"publisher","first-page":"9870","DOI":"10.1158\/0008-5472.Can-06-1679","volume":"66","author":"S Kondo","year":"2006","unstructured":"Kondo S, Seo SY, Yoshizaki T, Wakisaka N, Furukawa M, Joab I, et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res. 2006;66(20):9870\u20137. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-1679.","journal-title":"Cancer Res"},{"issue":"2","key":"590_CR70","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.canlet.2009.01.037","volume":"279","author":"JW Lee","year":"2009","unstructured":"Lee JW, Liu PF, Hsu LP, Chen PR, Chang CH, Shih WL. EBV LMP-1 negatively regulates expression and pro-apoptotic activity of Par-4 in nasopharyngeal carcinoma cells. Cancer Lett. 2009;279(2):193\u2013201. https:\/\/doi.org\/10.1016\/j.canlet.2009.01.037.","journal-title":"Cancer Lett"},{"issue":"7","key":"590_CR71","first-page":"2083","volume":"10","author":"Z Li","year":"2020","unstructured":"Li Z, Zhou Z, Wu X, Zhou Q, Liao C, Liu Y, et al. LMP1 promotes nasopharyngeal carcinoma metastasis through NTRK2-mediated anoikis resistance. Am J Cancer Res. 2020;10(7):2083\u201399.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"590_CR72","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.7150\/jca.37415","volume":"11","author":"D Ye","year":"2020","unstructured":"Ye D, Zhu J, Zhao Q, Ma W, Xiao Y, Xu G, et al. LMP1 Up-regulates calreticulin to induce epithelial-mesenchymal transition via TGF-\u03b2\/Smad3\/NRP1 pathway in nasopharyngeal carcinoma cells. J Cancer. 2020;11(5):1257\u201369. https:\/\/doi.org\/10.7150\/jca.37415.","journal-title":"J Cancer"},{"issue":"5","key":"590_CR73","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.Can-06-3933","volume":"67","author":"T Horikawa","year":"2007","unstructured":"Horikawa T, Yang J, Kondo S, Yoshizaki T, Joab I, Furukawa M, et al. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res. 2007;67(5):1970\u20138. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-3933.","journal-title":"Cancer Res"},{"issue":"7","key":"590_CR74","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/bjc.2011.38","volume":"104","author":"T Horikawa","year":"2011","unstructured":"Horikawa T, Yoshizaki T, Kondo S, Furukawa M, Kaizaki Y, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma. Br J Cancer. 2011;104(7):1160\u20137. https:\/\/doi.org\/10.1038\/bjc.2011.38.","journal-title":"Br J Cancer"},{"issue":"4","key":"590_CR75","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41419-021-03639-2","volume":"12","author":"S Xu","year":"2021","unstructured":"Xu S, Zhou Z, Peng X, Tao X, Zhou P, Zhang K, et al. EBV-LMP1 promotes radioresistance by inducing protective autophagy through BNIP3 in nasopharyngeal carcinoma. Cell Death Dis. 2021;12(4):344. https:\/\/doi.org\/10.1038\/s41419-021-03639-2.","journal-title":"Cell Death Dis"},{"issue":"5","key":"590_CR76","doi-asserted-by":"publisher","first-page":"e0194121","DOI":"10.1128\/jvi.01941-21","volume":"96","author":"N Zhu","year":"2022","unstructured":"Zhu N, Wang Q, Wu Z, Wang Y, Zeng MS, Yuan Y. Epstein-Barr virus LMP1-activated mTORC1 and mTORC2 coordinately promote nasopharyngeal cancer stem cell properties. J Virol. 2022;96(5):e0194121. https:\/\/doi.org\/10.1128\/jvi.01941-21.","journal-title":"J Virol"},{"issue":"1","key":"590_CR77","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13046-023-02835-6","volume":"42","author":"C Liao","year":"2023","unstructured":"Liao C, Li M, Chen X, Tang C, Quan J, Bode AM, et al. Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1\u03b1 promotes invasion and metastasis of nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2023;42(1):261. https:\/\/doi.org\/10.1186\/s13046-023-02835-6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"590_CR78","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1242\/bio.024646","volume":"6","author":"J Liang","year":"2017","unstructured":"Liang J, Zheng S, Xiao X, Wei J, Zhang Z, Ernberg I, et al. Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via the EGFR\/Ca(2+)\/calpain\/ITG\u03b24 axis. Biol Open. 2017;6(6):914\u201322. https:\/\/doi.org\/10.1242\/bio.024646.","journal-title":"Biol Open"},{"issue":"12","key":"590_CR79","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1128\/jvi.00174-12","volume":"86","author":"YY Lan","year":"2012","unstructured":"Lan YY, Hsiao JR, Chang KC, Chang JS, Chen CW, Lai HC, et al. Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK\/Fra-1-mediated induction of matrix metalloproteinase 9. J Virol. 2012;86(12):6656\u201367. https:\/\/doi.org\/10.1128\/jvi.00174-12.","journal-title":"J Virol"},{"issue":"2","key":"590_CR80","doi-asserted-by":"publisher","first-page":"113403","DOI":"10.1016\/j.yexcr.2022.113403","volume":"421","author":"T Cheng","year":"2022","unstructured":"Cheng T, Zhang S, Xia T, Zhang Y, Ji Y, Pan S, et al. EBV promotes vascular mimicry of dormant cancer cells by potentiating stemness and EMT. Exp Cell Res. 2022;421(2):113403. https:\/\/doi.org\/10.1016\/j.yexcr.2022.113403.","journal-title":"Exp Cell Res"},{"issue":"3","key":"590_CR81","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/path.4245","volume":"231","author":"RJ Port","year":"2013","unstructured":"Port RJ, Pinheiro-Maia S, Hu C, Arrand JR, Wei W, Young LS, et al. Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. J Pathol. 2013;231(3):367\u201377. https:\/\/doi.org\/10.1002\/path.4245.","journal-title":"J Pathol"},{"issue":"5","key":"590_CR82","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.3892\/ijo.2014.2342","volume":"44","author":"LF Yap","year":"2014","unstructured":"Yap LF, Ahmad M, Zabidi MM, Chu TL, Chai SJ, Lee HM, et al. Oncogenic effects of WNT5A in Epstein-Barr virus-associated nasopharyngeal carcinoma. Int J Oncol. 2014;44(5):1774\u201380. https:\/\/doi.org\/10.3892\/ijo.2014.2342.","journal-title":"Int J Oncol"},{"issue":"10","key":"590_CR83","doi-asserted-by":"publisher","first-page":"e1000170","DOI":"10.1371\/journal.ppat.1000170","volume":"4","author":"N Sivachandran","year":"2008","unstructured":"Sivachandran N, Sarkari F, Frappier L. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog. 2008;4(10):e1000170. https:\/\/doi.org\/10.1371\/journal.ppat.1000170.","journal-title":"PLoS Pathog"},{"issue":"Pt 11","key":"590_CR84","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1099\/vir.0.2008\/003392-0","volume":"89","author":"JD O\u2019Neil","year":"2008","unstructured":"O\u2019Neil JD, Owen TJ, Wood VHJ, Date KL, Valentine R, Chukwuma MB, et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol. 2008;89(Pt 11):2833\u201342. https:\/\/doi.org\/10.1099\/vir.0.2008\/003392-0.","journal-title":"J Gen Virol"},{"issue":"3","key":"590_CR85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cncr.28418","volume":"120","author":"L Wang","year":"2014","unstructured":"Wang L, Tian WD, Xu X, Nie B, Lu J, Liu X, et al. Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells. Cancer. 2014;120(3):363\u201372. https:\/\/doi.org\/10.1002\/cncr.28418.","journal-title":"Cancer"},{"issue":"6","key":"590_CR86","doi-asserted-by":"publisher","first-page":"e0032926","DOI":"10.1128\/mbio.00329-26","volume":"17","author":"S He","year":"2026","unstructured":"He S, Terhuja N, Soldan SS, Chen C, Cassel J, Yin X, et al. EBNA1 inhibitors reveal CDC7 and POU2F1 as direct functional targets in EBV epithelial cancers. MBio. 2026;17(6):e0032926. https:\/\/doi.org\/10.1128\/mbio.00329-26.","journal-title":"MBio"},{"issue":"15","key":"590_CR87","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1002\/cam4.3213","volume":"9","author":"J Wang","year":"2020","unstructured":"Wang J, Luo Y, Bi P, Lu J, Wang F, Liu X, et al. Mechanisms of Epstein-Barr virus nuclear antigen 1 favor Tregs accumulation in nasopharyngeal carcinoma. Cancer Med. 2020;9(15):5598\u2013608. https:\/\/doi.org\/10.1002\/cam4.3213.","journal-title":"Cancer Med"},{"key":"590_CR88","doi-asserted-by":"publisher","unstructured":"Huo S, Luo Y, Deng R, Liu X, Wang J, Wang L, et al. EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells. J Immunother Cancer. 2020;8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001588.","DOI":"10.1136\/jitc-2020-001588"},{"issue":"7","key":"590_CR89","first-page":"718","volume":"114","author":"L Yin","year":"2001","unstructured":"Yin L, Liao W, Deng X, Tang M, Gu H, Li X, et al. LMP1 activates NF-kappa B via degradation of I kappa B alpha in nasopharyngeal carcinoma cells. Chin Med J (Engl). 2001;114(7):718\u201322.","journal-title":"Chin Med J (Engl)"},{"key":"590_CR90","doi-asserted-by":"publisher","first-page":"640207","DOI":"10.3389\/fonc.2021.640207","volume":"11","author":"AK Lo","year":"2021","unstructured":"Lo AK, Dawson CW, Lung HL, Wong KL, Young LS. The role of EBV-encoded LMP1 in the NPC tumor microenvironment: from function to therapy. Front Oncol. 2021;11:640207. https:\/\/doi.org\/10.3389\/fonc.2021.640207.","journal-title":"Front Oncol"},{"issue":"24","key":"590_CR91","doi-asserted-by":"publisher","first-page":"15430","DOI":"10.1128\/jvi.79.24.15430-15442.2005","volume":"79","author":"DM Pegtel","year":"2005","unstructured":"Pegtel DM, Subramanian A, Sheen TS, Tsai CH, Golub TR, Thorley-Lawson DA. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol. 2005;79(24):15430\u201342. https:\/\/doi.org\/10.1128\/jvi.79.24.15430-15442.2005.","journal-title":"J Virol"},{"issue":"12","key":"590_CR92","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.18632\/oncotarget.23824","volume":"9","author":"CE Birdwell","year":"2018","unstructured":"Birdwell CE, Prasai K, Dykes S, Jia Y, Munroe TGC, Bienkowska-Haba M, et al. Epstein-Barr virus stably confers an invasive phenotype to epithelial cells through reprogramming of the WNT pathway. Oncotarget. 2018;9(12):10417\u201335. https:\/\/doi.org\/10.18632\/oncotarget.23824.","journal-title":"Oncotarget"},{"issue":"5","key":"590_CR93","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1158\/1078-0432.Ccr-24-2814","volume":"31","author":"AD Colevas","year":"2025","unstructured":"Colevas AD, Talebi Z, Winters E, Even C, Lee VH, Gillison ML, et al. First-in-human clinical trial of a small-molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr-positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies. Clin Cancer Res. 2025;31(5):815\u201323. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-2814.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"590_CR94","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3892\/or.19.2.319","volume":"19","author":"WK Yip","year":"2008","unstructured":"Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep. 2008;19(2):319\u201328. https:\/\/doi.org\/10.3892\/or.19.2.319.","journal-title":"Oncol Rep"},{"issue":"6779","key":"590_CR95","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/35008115","volume":"404","author":"RH Medema","year":"2000","unstructured":"Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000;404(6779):782\u20137. https:\/\/doi.org\/10.1038\/35008115.","journal-title":"Nature"},{"issue":"33","key":"590_CR96","doi-asserted-by":"publisher","first-page":"25865","DOI":"10.1074\/jbc.M004199200","volume":"275","author":"Y Tan","year":"2000","unstructured":"Tan Y, Demeter MR, Ruan H, Comb MJ. BAD Ser-155 phosphorylation regulates BAD\/Bcl-XL interaction and cell survival. J Biol Chem. 2000;275(33):25865\u20139. https:\/\/doi.org\/10.1074\/jbc.M004199200.","journal-title":"J Biol Chem"},{"issue":"1","key":"590_CR97","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1756-9966-29-34","volume":"29","author":"H Jiang","year":"2010","unstructured":"Jiang H, Fan D, Zhou G, Li X, Deng H. Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J Exp Clin Cancer Res. 2010;29(1):34. https:\/\/doi.org\/10.1186\/1756-9966-29-34.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"590_CR98","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/carcin\/bgs181","volume":"33","author":"XJ Li","year":"2012","unstructured":"Li XJ, Peng LX, Shao JY, Lu WH, Zhang JX, Chen S, et al. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis. 2012;33(7):1302\u20139. https:\/\/doi.org\/10.1093\/carcin\/bgs181.","journal-title":"Carcinogenesis"},{"issue":"1","key":"590_CR99","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12967-023-03986-y","volume":"21","author":"E Chen","year":"2023","unstructured":"Chen E, Huang J, Chen M, Wu J, Ouyang P, Wang X, et al. FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K\/AKT signaling pathway. J Transl Med. 2023;21(1):134. https:\/\/doi.org\/10.1186\/s12967-023-03986-y.","journal-title":"J Transl Med"},{"issue":"1","key":"590_CR100","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12967-022-03446-z","volume":"20","author":"Z Xie","year":"2022","unstructured":"Xie Z, Li W, Ai J, Xie J, Zhang X. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K\/AKT\/mTOR signaling pathway. J Transl Med. 2022;20(1):264. https:\/\/doi.org\/10.1186\/s12967-022-03446-z.","journal-title":"J Transl Med"},{"issue":"1","key":"590_CR101","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1186\/s12967-023-04654-x","volume":"21","author":"LZ Wu","year":"2023","unstructured":"Wu LZ, Zou Y, Wang BR, Ni HF, Kong YG, Hua QQ, et al. Enhancing nasopharyngeal carcinoma cell radiosensitivity by suppressing AKT\/mTOR via CENP-N knockdown. J Transl Med. 2023;21(1):792. https:\/\/doi.org\/10.1186\/s12967-023-04654-x.","journal-title":"J Transl Med"},{"issue":"5","key":"590_CR102","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.7150\/ijbs.69934","volume":"18","author":"J Jiang","year":"2022","unstructured":"Jiang J, Tang Q, Gong J, Jiang W, Chen Y, Zhou Q, et al. Radiosensitizer EXO-miR-197-3p inhibits nasopharyngeal carcinoma progression and radioresistance by regulating the AKT\/mTOR axis and HSPA5-mediated autophagy. Int J Biol Sci. 2022;18(5):1878\u201395. https:\/\/doi.org\/10.7150\/ijbs.69934.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"590_CR103","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1097\/js9.0000000000003607","volume":"112","author":"B Lin","year":"2026","unstructured":"Lin B, Xie G, Fu J, Zhang C, Qin M, Wang L, et al. Stabilization of VDAC1 by USP10 facilitates radioresistance and metastasis in nasopharyngeal carcinoma via MTOR-dependent autophagy pathway: an experimental study. Int J Surg. 2026;112(2):2668\u201382. https:\/\/doi.org\/10.1097\/js9.0000000000003607.","journal-title":"Int J Surg"},{"issue":"13","key":"590_CR104","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1128\/jvi.00344-10","volume":"84","author":"CP Kung","year":"2010","unstructured":"Kung CP, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 modulates distinctive NF- kappaB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression. J Virol. 2010;84(13):6605\u201314. https:\/\/doi.org\/10.1128\/jvi.00344-10.","journal-title":"J Virol"},{"key":"590_CR105","doi-asserted-by":"publisher","first-page":"14121","DOI":"10.1038\/ncomms14121","volume":"8","author":"YY Li","year":"2017","unstructured":"Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-\u03baB pathway activating mutations. Nat Commun. 2017;8:14121. https:\/\/doi.org\/10.1038\/ncomms14121.","journal-title":"Nat Commun"},{"issue":"1","key":"590_CR106","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/cr.2010.161","volume":"21","author":"VF Shih","year":"2011","unstructured":"Shih VF, Tsui R, Caldwell A, Hoffmann A. A single NF\u03baB system for both canonical and non-canonical signaling. Cell Res. 2011;21(1):86\u2013102. https:\/\/doi.org\/10.1038\/cr.2010.161.","journal-title":"Cell Res"},{"issue":"1","key":"590_CR107","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020;5(1):209. https:\/\/doi.org\/10.1038\/s41392-020-00312-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"590_CR108","doi-asserted-by":"publisher","first-page":"eabh2445","DOI":"10.1126\/sciadv.abh2445","volume":"8","author":"JK Tay","year":"2022","unstructured":"Tay JK, Zhu C, Shin JH, Zhu SX, Varma S, Foley JW, et al. The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-\u03baB signaling. Sci Adv. 2022;8(14):eabh2445. https:\/\/doi.org\/10.1126\/sciadv.abh2445.","journal-title":"Sci Adv"},{"issue":"2","key":"590_CR109","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.virol.2010.06.037","volume":"405","author":"HC Lai","year":"2010","unstructured":"Lai HC, Hsiao JR, Chen CW, Wu SY, Lee CH, Su IJ, et al. Endogenous latent membrane protein 1 in Epstein-Barr virus-infected nasopharyngeal carcinoma cells attracts T lymphocytes through upregulation of multiple chemokines. Virology. 2010;405(2):464\u201373. https:\/\/doi.org\/10.1016\/j.virol.2010.06.037.","journal-title":"Virology"},{"issue":"7","key":"590_CR110","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/hed.21270","volume":"32","author":"YT Huang","year":"2010","unstructured":"Huang YT, Liu MY, Tsai CH, Yeh TH. Upregulation of interleukin-1 by Epstein-Barr virus latent membrane protein 1 and its possible role in nasopharyngeal carcinoma cell growth. Head Neck. 2010;32(7):869\u201376. https:\/\/doi.org\/10.1002\/hed.21270.","journal-title":"Head Neck"},{"issue":"5","key":"590_CR111","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.gendis.2021.07.002","volume":"9","author":"L Yang","year":"2022","unstructured":"Yang L, Liu G, Li Y, Pan Y. The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: predictive value and immunotherapy implications. Genes Dis. 2022;9(5):1208\u201319. https:\/\/doi.org\/10.1016\/j.gendis.2021.07.002.","journal-title":"Genes Dis"},{"issue":"1","key":"590_CR112","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41467-021-21795-z","volume":"12","author":"L Gong","year":"2021","unstructured":"Gong L, Kwong DL, Dai W, Wu P, Li S, Yan Q, et al. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. Nat Commun. 2021;12(1):1540. https:\/\/doi.org\/10.1038\/s41467-021-21795-z.","journal-title":"Nat Commun"},{"issue":"2","key":"590_CR113","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00262-020-02681-x","volume":"70","author":"A Makowska","year":"2021","unstructured":"Makowska A, Meier S, Shen L, Busson P, Baloche V, Kontny U. Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1. Cancer Immunol Immunother. 2021;70(2):323\u201336. https:\/\/doi.org\/10.1007\/s00262-020-02681-x.","journal-title":"Cancer Immunol Immunother"},{"key":"590_CR114","doi-asserted-by":"publisher","unstructured":"Makowska A, Lelabi N, Nothbaum C, Shen L, Busson P, Tran TTB, et al. Radiotherapy combined with PD-1 inhibition increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells. Cells. 2021;10(9). https:\/\/doi.org\/10.3390\/cells10092458.","DOI":"10.3390\/cells10092458"},{"issue":"1","key":"590_CR115","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41419-025-07444-z","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Chen Y, Liu Y, Zhao J, Wang G, Chen H, et al. Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-\u03baB and STAT3 signaling pathways in nasopharyngeal carcinoma. Cell Death Dis. 2025;16(1):129. https:\/\/doi.org\/10.1038\/s41419-025-07444-z.","journal-title":"Cell Death Dis"},{"issue":"2","key":"590_CR116","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3892\/ijmm.21.2.153","volume":"21","author":"YP Liu","year":"2008","unstructured":"Liu YP, Tan YN, Wang ZL, Zeng L, Lu ZX, Li LL, et al. Phosphorylation and nuclear translocation of STAT3 regulated by the Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Int J Mol Med. 2008;21(2):153\u201362. https:\/\/doi.org\/10.3892\/ijmm.21.2.153.","journal-title":"Int J Mol Med"},{"issue":"16","key":"590_CR117","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/onc.2013.161","volume":"33","author":"Q Liao","year":"2014","unstructured":"Liao Q, Zeng Z, Guo X, Li X, Wei F, Zhang W, et al. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation. Oncogene. 2014;33(16):2098\u2013109. https:\/\/doi.org\/10.1038\/onc.2013.161.","journal-title":"Oncogene"},{"issue":"5","key":"590_CR118","doi-asserted-by":"publisher","first-page":"e62284","DOI":"10.1371\/journal.pone.0062284","volume":"8","author":"G Zhang","year":"2013","unstructured":"Zhang G, Tsang CM, Deng W, Yip YL, Lui VW, Wong SC, et al. Enhanced IL-6\/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells. PLoS One. 2013;8(5):e62284. https:\/\/doi.org\/10.1371\/journal.pone.0062284.","journal-title":"PLoS One"},{"issue":"1","key":"590_CR119","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7150\/ijbs.85341","volume":"20","author":"Y Zhan","year":"2024","unstructured":"Zhan Y, Wang W, Wang H, Xu Y, Zhang Y, Ning Y, et al. G3BP1 interact with JAK2 mRNA to promote the malignant progression of nasopharyngeal carcinoma via activating JAK2\/STAT3 signaling pathway. Int J Biol Sci. 2024;20(1):94\u2013112. https:\/\/doi.org\/10.7150\/ijbs.85341.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"590_CR120","doi-asserted-by":"publisher","first-page":"101362","DOI":"10.1016\/j.bjorl.2023.101362","volume":"90","author":"T Kaisai","year":"2024","unstructured":"Kaisai T, Mantang Z, Tailei Y, Liying Z, Xiaoping C, Mingming J, et al. Hsa_circ_0013561 promotes progression of nasopharyngeal carcinoma by activating JAK2\/STAT3 signaling pathway. Braz J Otorhinolaryngol. 2024;90(1):101362. https:\/\/doi.org\/10.1016\/j.bjorl.2023.101362.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"2","key":"590_CR121","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.bjc.6601003","volume":"89","author":"JR Hsiao","year":"2003","unstructured":"Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer. 2003;89(2):344\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6601003.","journal-title":"Br J Cancer"},{"issue":"8","key":"590_CR122","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/ijc.24567","volume":"125","author":"VW Lui","year":"2009","unstructured":"Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, et al. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer. 2009;125(8):1884\u201393. https:\/\/doi.org\/10.1002\/ijc.24567.","journal-title":"Int J Cancer"},{"issue":"1","key":"590_CR123","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3892\/mmr.2020.11112","volume":"22","author":"LH Bian","year":"2020","unstructured":"Bian LH, Duan JL, Zhou C, Shen GW, Wang XY, Yang Y, et al. MicroRNA-19b inhibitors can attenuate the STAT3 signaling pathway in NPC C666\u20131 cells. Mol Med Rep. 2020;22(1):51\u20136. https:\/\/doi.org\/10.3892\/mmr.2020.11112.","journal-title":"Mol Med Rep"},{"key":"590_CR124","doi-asserted-by":"publisher","first-page":"651693","DOI":"10.3389\/fonc.2021.651693","volume":"11","author":"X Zhu","year":"2021","unstructured":"Zhu X, Liu L, Wang Y, Cong J, Lin Z, Wang Y, et al. lncRNA MIAT\/HMGB1 axis is involved in cisplatin resistance via regulating IL6-mediated activation of the JAK2\/STAT3 pathway in nasopharyngeal carcinoma. Front Oncol. 2021;11:651693. https:\/\/doi.org\/10.3389\/fonc.2021.651693.","journal-title":"Front Oncol"},{"issue":"5","key":"590_CR125","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/01.lab.0000067480.44925.10","volume":"83","author":"AK Lo","year":"2003","unstructured":"Lo AK, Liu Y, Wang XH, Huang DP, Yuen PW, Wong YC, et al. Alterations of biologic properties and gene expression in nasopharyngeal epithelial cells by the Epstein-Barr virus-encoded latent membrane protein 1. Lab Invest. 2003;83(5):697\u2013709. https:\/\/doi.org\/10.1097\/01.lab.0000067480.44925.10.","journal-title":"Lab Invest"},{"issue":"1","key":"590_CR126","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12967-023-04673-8","volume":"21","author":"PY Siak","year":"2023","unstructured":"Siak PY, Heng WS, Teoh SSH, Lwin YY, Cheah SC. Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect. J Transl Med. 2023;21(1):786. https:\/\/doi.org\/10.1186\/s12967-023-04673-8.","journal-title":"J Transl Med"},{"key":"590_CR127","doi-asserted-by":"publisher","first-page":"104100","DOI":"10.1016\/j.ebiom.2022.104100","volume":"81","author":"S Ding","year":"2022","unstructured":"Ding S, Gao Y, Lv D, Tao Y, Liu S, Chen C, et al. DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway. EBioMedicine. 2022;81:104100. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104100.","journal-title":"EBioMedicine"},{"issue":"11","key":"590_CR128","doi-asserted-by":"publisher","first-page":"8811","DOI":"10.1007\/s13277-015-3595-8","volume":"36","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Zou C, Zhang Z, Qian CN, Yang X, Shi J, et al. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expressions. Tumour Biol. 2015;36(11):8811\u20138. https:\/\/doi.org\/10.1007\/s13277-015-3595-8.","journal-title":"Tumour Biol"},{"issue":"6","key":"590_CR129","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/15384047.2018.1450119","volume":"19","author":"F Liu","year":"2018","unstructured":"Liu F, Tai Y, Ma J. LncRNA NEAT1\/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway. Cancer Biol Ther. 2018;19(6):534\u201342. https:\/\/doi.org\/10.1080\/15384047.2018.1450119.","journal-title":"Cancer Biol Ther"},{"issue":"19","key":"590_CR130","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1002\/cam4.3356","volume":"9","author":"J Wang","year":"2020","unstructured":"Wang J, Yao Z, Lai X, Bao H, Li Y, Li S, et al. Tetrandrine sensitizes nasopharyngeal carcinoma cells to irradiation by inducing autophagy and inhibiting MEK\/ERK pathway. Cancer Med. 2020;9(19):7268\u201378. https:\/\/doi.org\/10.1002\/cam4.3356.","journal-title":"Cancer Med"},{"issue":"9","key":"590_CR131","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/cad.0000000000001092","volume":"32","author":"X Gong","year":"2021","unstructured":"Gong X, Fan L, Wang P. MEK inhibition by trametinib overcomes chemoresistance in preclinical nasopharyngeal carcinoma models. Anticancer Drugs. 2021;32(9):978\u201385. https:\/\/doi.org\/10.1097\/cad.0000000000001092.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"590_CR132","first-page":"2699","volume":"11","author":"YJ Zhang","year":"2018","unstructured":"Zhang YJ, Zhang MF, Zhou HF, Yang J. Activation of c-Jun\/JNK signaling predicts poor prognosis in nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2018;11(5):2699\u2013706.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"590_CR133","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1128\/mcb.24.1.192-199.2004","volume":"24","author":"J Wan","year":"2004","unstructured":"Wan J, Sun L, Mendoza JW, Chui YL, Huang DP, Chen ZJ, et al. Elucidation of the c-Jun N-terminal kinase pathway mediated by Estein-Barr virus-encoded latent membrane protein 1. Mol Cell Biol. 2004;24(1):192\u20139. https:\/\/doi.org\/10.1128\/mcb.24.1.192-199.2004.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"590_CR134","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1128\/mcb.26.2.448-456.2006","volume":"26","author":"J Wan","year":"2006","unstructured":"Wan J, Zhang W, Wu L, Bai T, Zhang M, Lo KW, et al. BS69, a specific adaptor in the latent membrane protein 1-mediated c-Jun N-terminal kinase pathway. Mol Cell Biol. 2006;26(2):448\u201356. https:\/\/doi.org\/10.1128\/mcb.26.2.448-456.2006.","journal-title":"Mol Cell Biol"},{"issue":"18","key":"590_CR135","doi-asserted-by":"publisher","first-page":"9556","DOI":"10.1128\/jvi.76.18.9556-9561.2002","volume":"76","author":"SY Chen","year":"2002","unstructured":"Chen SY, Lu J, Shih YC, Tsai CH. Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol. 2002;76(18):9556\u201361. https:\/\/doi.org\/10.1128\/jvi.76.18.9556-9561.2002.","journal-title":"J Virol"},{"issue":"6","key":"590_CR136","doi-asserted-by":"publisher","first-page":"e38737","DOI":"10.1371\/journal.pone.0038737","volume":"7","author":"J Ou","year":"2012","unstructured":"Ou J, Luan W, Deng J, Sa R, Liang H. \u03b1V integrin induces multicellular radioresistance in human nasopharyngeal carcinoma via activating SAPK\/JNK pathway. PLoS One. 2012;7(6):e38737. https:\/\/doi.org\/10.1371\/journal.pone.0038737.","journal-title":"PLoS One"},{"issue":"24","key":"590_CR137","doi-asserted-by":"publisher","first-page":"11668","DOI":"10.1158\/0008-5472.Can-06-2194","volume":"66","author":"CL Tsai","year":"2006","unstructured":"Tsai CL, Li HP, Lu YJ, Hsueh C, Liang Y, Chen CL, et al. Activation of DNA methyltransferase 1 by EBV LMP1 involves c-jun NH(2)-terminal kinase signaling. Cancer Res. 2006;66(24):11668\u201376. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-2194.","journal-title":"Cancer Res"},{"issue":"3","key":"590_CR138","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3892\/or.2014.3692","volume":"33","author":"SY Guo","year":"2015","unstructured":"Guo SY, Zhu XD, Ge LY, Qu S, Li L, Su F, et al. RNAi-mediated knockdown of the c-jun gene sensitizes radioresistant human nasopharyngeal carcinoma cell line CNE-2R to radiation. Oncol Rep. 2015;33(3):1155\u201360. https:\/\/doi.org\/10.3892\/or.2014.3692.","journal-title":"Oncol Rep"},{"issue":"2","key":"590_CR139","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2217\/epi.14.79","volume":"7","author":"L Li","year":"2015","unstructured":"Li L, Zhang Y, Fan Y, Sun K, Su X, Du Z, et al. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics. 2015;7(2):155\u201373. https:\/\/doi.org\/10.2217\/epi.14.79.","journal-title":"Epigenomics"},{"issue":"1","key":"590_CR140","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13148-018-0535-7","volume":"10","author":"J Fan","year":"2018","unstructured":"Fan J, Zhang Y, Mu J, He X, Shao B, Zhou D, et al. TET1 exerts its anti-tumor functions via demethylating DACT2 and SFRP2 to antagonize Wnt\/\u03b2-catenin signaling pathway in nasopharyngeal carcinoma cells. Clin Epigenetics. 2018;10(1):103. https:\/\/doi.org\/10.1186\/s13148-018-0535-7.","journal-title":"Clin Epigenetics"},{"issue":"22","key":"590_CR141","doi-asserted-by":"publisher","first-page":"12276","DOI":"10.1128\/jvi.77.22.12276-12284.2003","volume":"77","author":"JA Morrison","year":"2003","unstructured":"Morrison JA, Klingelhutz AJ, Raab-Traub N. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol. 2003;77(22):12276\u201384. https:\/\/doi.org\/10.1128\/jvi.77.22.12276-12284.2003.","journal-title":"J Virol"},{"key":"590_CR142","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12935-019-0764-7","volume":"19","author":"PY Jin","year":"2019","unstructured":"Jin PY, Zheng ZH, Lu HJ, Yan J, Zheng GH, Zheng YL, et al. Roles of \u03b2-catenin, TCF-4, and survivin in nasopharyngeal carcinoma: correlation with clinicopathological features and prognostic significance. Cancer Cell Int. 2019;19:48. https:\/\/doi.org\/10.1186\/s12935-019-0764-7.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"590_CR143","first-page":"72","volume":"28","author":"FL Wang","year":"2009","unstructured":"Wang FL, Guo X, Yuan TZ, Cao SM, Rao HL, Hou JH, et al. Expression and clinical significance of Wnt-1 and beta-catenin in nasopharyngeal carcinoma. Ai Zheng. 2009;28(1):72\u20135.","journal-title":"Ai Zheng"},{"issue":"4","key":"590_CR144","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/curroncol28040230","volume":"28","author":"C Ngernsombat","year":"2021","unstructured":"Ngernsombat C, Prattapong P, Larbcharoensub N, Khotthong K, Janvilisri T. WNT8B as an independent prognostic marker for nasopharyngeal carcinoma. Curr Oncol. 2021;28(4):2529\u201339. https:\/\/doi.org\/10.3390\/curroncol28040230.","journal-title":"Curr Oncol"},{"issue":"5","key":"590_CR145","doi-asserted-by":"publisher","first-page":"E320","DOI":"10.25011\/cim.v37i5.22012","volume":"37","author":"D Hao","year":"2014","unstructured":"Hao D, Phan T, Jagdis A, Siever JE, Klimowicz AC, Laskin JJ, et al. Evaluation of E-cadherin, \u03b2-catenin and vimentin protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients. Clin Invest Med. 2014;37(5):E320\u201330. https:\/\/doi.org\/10.25011\/cim.v37i5.22012.","journal-title":"Clin Invest Med"},{"issue":"1","key":"590_CR146","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4143\/crt.2014.311","volume":"48","author":"D Zong","year":"2016","unstructured":"Zong D, Yin L, Zhong Q, Guo WJ, Xu JH, Jiang N, et al. ZNF488 enhances the invasion and tumorigenesis in nasopharyngeal carcinoma via the Wnt signaling pathway involving epithelial mesenchymal transition. Cancer Res Treat. 2016;48(1):334\u201344. https:\/\/doi.org\/10.4143\/crt.2014.311.","journal-title":"Cancer Res Treat"},{"issue":"6","key":"590_CR147","doi-asserted-by":"publisher","first-page":"e2838","DOI":"10.1038\/cddis.2017.114","volume":"8","author":"T Zhang","year":"2017","unstructured":"Zhang T, Yin P, Zhang Z, Xu B, Che D, Dai Z, et al. Deficiency of pigment epithelium-derived factor in nasopharyngeal carcinoma cells triggers the epithelial-mesenchymal transition and metastasis. Cell Death Dis. 2017;8(6):e2838. https:\/\/doi.org\/10.1038\/cddis.2017.114.","journal-title":"Cell Death Dis"},{"issue":"2","key":"590_CR148","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/j.canep.2011.11.002","volume":"36","author":"Y Song","year":"2012","unstructured":"Song Y, Yang QX, Zhang F, Meng F, Li H, Dong Y, et al. Suppression of nasopharyngeal carcinoma cell by targeting \u03b2-catenin signaling pathway. Cancer Epidemiol. 2012;36(2):e116\u201321. https:\/\/doi.org\/10.1016\/j.canep.2011.11.002.","journal-title":"Cancer Epidemiol"},{"issue":"16","key":"590_CR149","doi-asserted-by":"publisher","first-page":"14428","DOI":"10.18632\/oncotarget.3982","volume":"6","author":"Y Cheng","year":"2015","unstructured":"Cheng Y, Phoon YP, Jin X, Chong SY, Ip JC, Wong BW, et al. Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment. Oncotarget. 2015;6(16):14428\u201339. https:\/\/doi.org\/10.18632\/oncotarget.3982.","journal-title":"Oncotarget"},{"key":"590_CR150","doi-asserted-by":"publisher","first-page":"9979","DOI":"10.1038\/srep09979","volume":"5","author":"KC Chan","year":"2015","unstructured":"Chan KC, Chan LS, Ip JC, Lo C, Yip TT, Ngan RK, et al. Therapeutic targeting of CBP\/\u03b2-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Sci Rep. 2015;5:9979. https:\/\/doi.org\/10.1038\/srep09979.","journal-title":"Sci Rep"},{"issue":"7","key":"590_CR151","doi-asserted-by":"publisher","first-page":"e18130","DOI":"10.1016\/j.heliyon.2023.e18130","volume":"9","author":"H Wang","year":"2023","unstructured":"Wang H, Luo K, Zhan Y, Peng S, Fan S, Wang W. Role of \u03b2-catenin in PD-L1 expression of nasopharyngeal carcinoma. Heliyon. 2023;9(7):e18130. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18130.","journal-title":"Heliyon"},{"issue":"1","key":"590_CR152","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62. https:\/\/doi.org\/10.1186\/s12935-020-01719-5.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"590_CR153","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2007.01.012","volume":"253","author":"FL Sung","year":"2007","unstructured":"Sung FL, Hui EP, Tao Q, Li H, Tsui NB, Lo YM, et al. Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett. 2007;253(1):74\u201388. https:\/\/doi.org\/10.1016\/j.canlet.2007.01.012.","journal-title":"Cancer Lett"},{"issue":"12","key":"590_CR154","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12032-014-0304-1","volume":"31","author":"Y Chen","year":"2014","unstructured":"Chen Y, Li X, Wu S, Xu G, Zhou Y, Gong L, et al. Expression of HIF-1\u03b1 and CAIX in nasopharyngeal carcinoma and their correlation with patients\u2019 prognosis. Med Oncol. 2014;31(12):304. https:\/\/doi.org\/10.1007\/s12032-014-0304-1.","journal-title":"Med Oncol"},{"issue":"8","key":"590_CR155","first-page":"2595","volume":"8","author":"EP Hui","year":"2002","unstructured":"Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002;8(8):2595\u2013604.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"590_CR156","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2016.08.021","volume":"382","author":"WW Sung","year":"2016","unstructured":"Sung WW, Chu YC, Chen PR, Liao MH, Lee JW. Positive regulation of HIF-1A expression by EBV oncoprotein LMP1 in nasopharyngeal carcinoma cells. Cancer Lett. 2016;382(1):21\u201331. https:\/\/doi.org\/10.1016\/j.canlet.2016.08.021.","journal-title":"Cancer Lett"},{"issue":"3","key":"590_CR157","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41419-018-0425-0","volume":"9","author":"Y Shan","year":"2018","unstructured":"Shan Y, You B, Shi S, Shi W, Zhang Z, Zhang Q, et al. Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 2018;9(3):382. https:\/\/doi.org\/10.1038\/s41419-018-0425-0.","journal-title":"Cell Death Dis"},{"issue":"6","key":"590_CR158","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/mc.23525","volume":"62","author":"L Xie","year":"2023","unstructured":"Xie L, Zhang K, You B, Yin H, Zhang P, Shan Y, et al. Hypoxic nasopharyngeal carcinoma-derived exosomal miR-455 increases vascular permeability by targeting ZO-1 to promote metastasis. Mol Carcinog. 2023;62(6):803\u201319. https:\/\/doi.org\/10.1002\/mc.23525.","journal-title":"Mol Carcinog"},{"issue":"1","key":"590_CR159","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.yexcr.2017.08.005","volume":"359","author":"WW Sung","year":"2017","unstructured":"Sung WW, Chen PR, Liao MH, Lee JW. Enhanced aerobic glycolysis of nasopharyngeal carcinoma cells by Epstein-Barr virus latent membrane protein 1. Exp Cell Res. 2017;359(1):94\u2013100. https:\/\/doi.org\/10.1016\/j.yexcr.2017.08.005.","journal-title":"Exp Cell Res"},{"issue":"8","key":"590_CR160","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.clon.2008.07.001","volume":"20","author":"L Xueguan","year":"2008","unstructured":"Xueguan L, Xiaoshen W, Yongsheng Z, Chaosu H, Chunying S, Yan F. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol (R Coll Radiol). 2008;20(8):606\u201312. https:\/\/doi.org\/10.1016\/j.clon.2008.07.001.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"590_CR161","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/cco.2016.03.16","volume":"5","author":"C Yip","year":"2016","unstructured":"Yip C, Cook GJ, Wee J, Fong KW, Tan T, Goh V. Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging. Chin Clin Oncol. 2016;5(2):24. https:\/\/doi.org\/10.21037\/cco.2016.03.16.","journal-title":"Chin Clin Oncol"},{"key":"590_CR162","doi-asserted-by":"publisher","first-page":"110686","DOI":"10.1016\/j.radonc.2024.110686","volume":"203","author":"X Huang","year":"2025","unstructured":"Huang X, Lin K, Chen W, Zhang D, Khan M, Ye X, et al. Modulation of the local angiotensin II: suppression of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1\u03b1-HILPDA axis. Radiother Oncol. 2025;203:110686. https:\/\/doi.org\/10.1016\/j.radonc.2024.110686.","journal-title":"Radiother Oncol"},{"issue":"1","key":"590_CR163","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41467-025-56134-z","volume":"16","author":"R Zhang","year":"2025","unstructured":"Zhang R, Shen Y, Zhou X, Li J, Zhao H, Zhang Z, et al. Hypoxia-tropic delivery of nanozymes targeting transferrin receptor 1 for nasopharyngeal carcinoma radiotherapy sensitization. Nat Commun. 2025;16(1):890. https:\/\/doi.org\/10.1038\/s41467-025-56134-z.","journal-title":"Nat Commun"},{"issue":"7","key":"590_CR164","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00262-025-04047-7","volume":"74","author":"X Yuan","year":"2025","unstructured":"Yuan X, Liu X, Jiang D, Zheng Z, Ma X, Wu S, et al. Exosomal PD-L1 derived from hypoxia nasopharyngeal carcinoma cell exacerbates CD8(+) T cell suppression by promoting PD-L1 upregulation in macrophages. Cancer Immunol Immunother. 2025;74(7):220. https:\/\/doi.org\/10.1007\/s00262-025-04047-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"590_CR165","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1158\/0008-5472.Can-17-1143","volume":"77","author":"J Yuan","year":"2017","unstructured":"Yuan J, Jiang YY, Mayakonda A, Huang M, Ding LW, Lin H, et al. Super-enhancers promote transcriptional dysregulation in nasopharyngeal carcinoma. Cancer Res. 2017;77(23):6614\u201326. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1143.","journal-title":"Cancer Res"},{"key":"590_CR166","doi-asserted-by":"publisher","unstructured":"Liu X, Li Y, Zhou X, Zhu S, Kaya NA, Chan YS, et al. An integrative analysis of nasopharyngeal carcinoma genomes unraveled unique processes driving a viral-positive cancer. Cancers (Basel). 2023;15(4). https:\/\/doi.org\/10.3390\/cancers15041243.","DOI":"10.3390\/cancers15041243"},{"issue":"50","key":"590_CR167","doi-asserted-by":"publisher","first-page":"e36583","DOI":"10.1097\/md.0000000000036583","volume":"102","author":"T Qian","year":"2023","unstructured":"Qian T, Zhou Z, Zhang Q, Liou YL, Zhou H. SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: a reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer. Medicine (Baltimore). 2023;102(50):e36583. https:\/\/doi.org\/10.1097\/md.0000000000036583.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"590_CR168","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41419-020-03054-z","volume":"11","author":"YY Liang","year":"2020","unstructured":"Liang YY, Deng XB, Lin XT, Jiang LL, Huang XT, Mo ZW, et al. RASSF1A inhibits PDGFB-driven malignant phenotypes of nasopharyngeal carcinoma cells in a YAP1-dependent manner. Cell Death Dis. 2020;11(10):855. https:\/\/doi.org\/10.1038\/s41419-020-03054-z.","journal-title":"Cell Death Dis"},{"issue":"3","key":"590_CR169","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/03936155241268431","volume":"39","author":"TD Lao","year":"2024","unstructured":"Lao TD, Le TAH. Hypermethylation of genes on chromosome 3p as a biomarker for nasopharyngeal carcinoma diagnosis: a Vietnamese case-control study. Int J Biol Markers. 2024;39(3):201\u20138. https:\/\/doi.org\/10.1177\/03936155241268431.","journal-title":"Int J Biol Markers"},{"issue":"2","key":"590_CR170","doi-asserted-by":"publisher","first-page":"166598","DOI":"10.1016\/j.bbadis.2022.166598","volume":"1869","author":"S Kondo","year":"2023","unstructured":"Kondo S, Okabe A, Nakagawa T, Matsusaka K, Fukuyo M, Rahmutulla B, et al. Repression of DERL3 via DNA methylation by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Biochim Biophys Acta Mol Basis Dis. 2023;1869(2):166598. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166598.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"28","key":"590_CR171","doi-asserted-by":"publisher","first-page":"14144","DOI":"10.1073\/pnas.1821752116","volume":"116","author":"MML Leong","year":"2019","unstructured":"Leong MML, Cheung AKL, Dai W, Tsao SW, Tsang CM, Dawson CW, et al. EBV infection is associated with histone bivalent switch modifications in squamous epithelial cells. Proc Natl Acad Sci U S A. 2019;116(28):14144\u201353. https:\/\/doi.org\/10.1073\/pnas.1821752116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"590_CR172","doi-asserted-by":"publisher","first-page":"104870","DOI":"10.1016\/j.ebiom.2023.104870","volume":"98","author":"SX Liu","year":"2023","unstructured":"Liu SX, Wang C, Lin RB, Ding WY, Roy G, Wang HB, et al. Super-enhancer driven SOX2 promotes tumor formation by chromatin re-organization in nasopharyngeal carcinoma. EBioMedicine. 2023;98:104870. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104870.","journal-title":"EBioMedicine"},{"issue":"36","key":"590_CR173","doi-asserted-by":"publisher","first-page":"9683","DOI":"10.1073\/pnas.1705236114","volume":"114","author":"L Ke","year":"2017","unstructured":"Ke L, Zhou H, Wang C, Xiong G, Xiang Y, Ling Y, et al. Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis. Proc Natl Acad Sci U S A. 2017;114(36):9683\u20138. https:\/\/doi.org\/10.1073\/pnas.1705236114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"590_CR174","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41419-023-05985-9","volume":"14","author":"Q Jia","year":"2023","unstructured":"Jia Q, Tan Y, Li Y, Wu Y, Wang J, Tang F. JUN-induced super-enhancer RNA forms R-loop to promote nasopharyngeal carcinoma metastasis. Cell Death Dis. 2023;14(7):459. https:\/\/doi.org\/10.1038\/s41419-023-05985-9.","journal-title":"Cell Death Dis"},{"issue":"11","key":"590_CR175","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012\u201327. https:\/\/doi.org\/10.1016\/j.tig.2021.05.002.","journal-title":"Trends Genet"},{"key":"590_CR176","doi-asserted-by":"publisher","first-page":"102430","DOI":"10.1016\/j.sbi.2022.102430","volume":"75","author":"S Li","year":"2022","unstructured":"Li S, Peng Y, Panchenko AR. DNA methylation: precise modulation of chromatin structure and dynamics. Curr Opin Struct Biol. 2022;75:102430. https:\/\/doi.org\/10.1016\/j.sbi.2022.102430.","journal-title":"Curr Opin Struct Biol"},{"issue":"12","key":"590_CR177","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1158\/1535-7163.Mct-15-0260","volume":"14","author":"W Jiang","year":"2015","unstructured":"Jiang W, Liu N, Chen XZ, Sun Y, Li B, Ren XY, et al. Genome-wide identification of a methylation gene panel as a prognostic biomarker in nasopharyngeal carcinoma. Mol Cancer Ther. 2015;14(12):2864\u201373. https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0260.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"590_CR178","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/cam4.451","volume":"4","author":"W Dai","year":"2015","unstructured":"Dai W, Cheung AK, Ko JM, Cheng Y, Zheng H, Ngan RK, et al. Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. Cancer Med. 2015;4(7):1079\u201390. https:\/\/doi.org\/10.1002\/cam4.451.","journal-title":"Cancer Med"},{"issue":"3","key":"590_CR179","doi-asserted-by":"publisher","first-page":"874","DOI":"10.7150\/jca.49392","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhou C, Li H, Li H, Li Y. Identifying key genes for nasopharyngeal carcinoma by prioritized consensus differentially expressed genes caused by aberrant methylation. J Cancer. 2021;12(3):874\u201384. https:\/\/doi.org\/10.7150\/jca.49392.","journal-title":"J Cancer"},{"issue":"4","key":"590_CR180","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3892\/ijo.22.4.869","volume":"22","author":"TS Wong","year":"2003","unstructured":"Wong TS, Tang KC, Kwong DL, Sham JS, Wei WI, Kwong YL, et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. Int J Oncol. 2003;22(4):869\u201374. https:\/\/doi.org\/10.3892\/ijo.22.4.869.","journal-title":"Int J Oncol"},{"issue":"10","key":"590_CR181","first-page":"3877","volume":"61","author":"KW Lo","year":"2001","unstructured":"Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001;61(10):3877\u201381.","journal-title":"Cancer Res"},{"issue":"4","key":"590_CR182","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 2016;8(4):a019521. https:\/\/doi.org\/10.1101\/cshperspect.a019521.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"590_CR183","doi-asserted-by":"publisher","first-page":"109595","DOI":"10.1016\/j.radonc.2023.109595","volume":"183","author":"Z Wu","year":"2023","unstructured":"Wu Z, Qi B, Lin FF, Zhang L, He Q, Li FP, et al. Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation. Radiother Oncol. 2023;183:109595. https:\/\/doi.org\/10.1016\/j.radonc.2023.109595.","journal-title":"Radiother Oncol"},{"issue":"4","key":"590_CR184","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up(\u2020). Ann Oncol. 2021;32(4):452\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.007.","journal-title":"Ann Oncol"},{"issue":"2","key":"590_CR185","doi-asserted-by":"publisher","first-page":"55","DOI":"10.22543\/2392-7674.1548","volume":"11","author":"AA Alexe","year":"2024","unstructured":"Alexe AA, Lupascu MV, Septar H, Pantea Stoian A, Suceveanu AI, Gherghina V, et al. Challenges in diagnosing nasopharyngeal tumors. J Mind Med Sci. 2024;11(2):437-43. https:\/\/doi.org\/10.22543\/2392-7674.1548.","journal-title":"J Mind Med Sci"},{"issue":"3","key":"590_CR186","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/cncr.24049","volume":"115","author":"L Tang","year":"2009","unstructured":"Tang L, Mao Y, Liu L, Liang S, Chen Y, Sun Y, et al. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging. Cancer (Phila). 2009;115(3):680\u20138. https:\/\/doi.org\/10.1002\/cncr.24049.","journal-title":"Cancer (Phila)"},{"issue":"5","key":"590_CR187","doi-asserted-by":"publisher","first-page":"e8199","DOI":"10.7759\/cureus.8199","volume":"12","author":"N Alsafadi","year":"2020","unstructured":"Alsafadi N, Alqarni MS, Attar M, Mgarry R, Bokhari A. Nasopharyngeal cancer: prevalence, outcome, and impact on health-related quality of life at Princess Norah Oncology Center, Jeddah, Saudi Arabia. Cureus. 2020;12(5):e8199. https:\/\/doi.org\/10.7759\/cureus.8199.","journal-title":"Cureus"},{"key":"590_CR188","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.radonc.2021.08.022","volume":"163","author":"JCH Chow","year":"2021","unstructured":"Chow JCH, Lee A, Bao KKH, Cheung KM, Chan JCH, Tam AHP, et al. Cranial neuropathies in advanced nasopharyngeal carcinoma: neurological recovery after modern radiotherapy and systemic chemotherapy. Radiother Oncol. 2021;163:221\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2021.08.022.","journal-title":"Radiother Oncol"},{"issue":"1","key":"590_CR189","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13014-021-01846-x","volume":"16","author":"J Zang","year":"2021","unstructured":"Zang J, Li Y, Luo S, Wang J, Hou B, Yao M, et al. Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma. Radiat Oncol. 2021;16(1):118. https:\/\/doi.org\/10.1186\/s13014-021-01846-x.","journal-title":"Radiat Oncol"},{"issue":"17","key":"590_CR190","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1002\/cam4.3301","volume":"9","author":"W Qu","year":"2020","unstructured":"Qu W, Li S, Zhang M, Qiao Q. Pattern and prognosis of distant metastases in nasopharyngeal carcinoma: a large\u2010population retrospective analysis. Cancer Med. 2020;9(17):6147\u201358. https:\/\/doi.org\/10.1002\/cam4.3301.","journal-title":"Cancer Med"},{"issue":"1102","key":"590_CR191","doi-asserted-by":"publisher","first-page":"20190107","DOI":"10.1259\/bjr.20190107","volume":"92","author":"L Claude","year":"2019","unstructured":"Claude L, Jouglar E, Duverge L, Orbach D. Update in pediatric nasopharyngeal undifferentiated carcinoma. Br J Radiol. 2019;92(1102):20190107. https:\/\/doi.org\/10.1259\/bjr.20190107.","journal-title":"Br J Radiol"},{"issue":"3","key":"590_CR192","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/mph.0000000000002848","volume":"46","author":"T Ben-Ami","year":"2024","unstructured":"Ben-Ami T. Nasopharyngeal carcinoma in children, current treatment approach. J Pediatr Hematol Oncol. 2024;46(3):117\u201324. https:\/\/doi.org\/10.1097\/mph.0000000000002848.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"590_CR193","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1148\/radiol.10101241","volume":"258","author":"AD King","year":"2011","unstructured":"King AD, Vlantis AC, Bhatia KS, Zee BC, Woo JK, Tse GM, et al. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. Radiology. 2011;258(2):531\u20137. https:\/\/doi.org\/10.1148\/radiol.10101241.","journal-title":"Radiology"},{"issue":"18","key":"590_CR194","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/cncr.33552","volume":"127","author":"Z Liu","year":"2021","unstructured":"Liu Z, Li H, Yu KJ, Xie SH, King AD, Ai QH, et al. Comparison of new magnetic resonance imaging grading system with conventional endoscopy for the early detection of nasopharyngeal carcinoma. Cancer. 2021;127(18):3403\u201312. https:\/\/doi.org\/10.1002\/cncr.33552.","journal-title":"Cancer"},{"issue":"4","key":"590_CR195","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/jnci\/djad012","volume":"115","author":"WKJ Lam","year":"2023","unstructured":"Lam WKJ, King AD, Miller JA, Liu Z, Yu KJ, Chua MLK, et al. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions. J Natl Cancer Inst. 2023;115(4):355\u201364. https:\/\/doi.org\/10.1093\/jnci\/djad012.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"590_CR196","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41416-019-0575-6","volume":"121","author":"JM Nicholls","year":"2019","unstructured":"Nicholls JM, Lee VH, Chan SK, Tsang KC, Choi CW, Kwong DL, et al. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. Br J Cancer. 2019;121(8):690\u20138. https:\/\/doi.org\/10.1038\/s41416-019-0575-6.","journal-title":"Br J Cancer"},{"issue":"12","key":"590_CR197","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/jamaoncol.2024.4354","volume":"10","author":"JJ Pan","year":"2024","unstructured":"Pan JJ, Mai HQ, Ng WT, Hu CS, Li JG, Chen XZ, et al. Ninth version of the AJCC and UICC nasopharyngeal cancer TNM staging classification. JAMA Oncol. 2024;10(12):1627\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4354.","journal-title":"JAMA Oncol"},{"issue":"9","key":"590_CR198","doi-asserted-by":"publisher","first-page":"e2124721","DOI":"10.1001\/jamanetworkopen.2021.24721","volume":"4","author":"WZ Li","year":"2021","unstructured":"Li WZ, Wu HJ, Lv SH, Hu XF, Liang H, Liu GY, et al. Assessment of survival model performance following inclusion of Epstein-Barr virus DNA status in conventional TNM staging groups in Epstein-Barr virus-related nasopharyngeal carcinoma. JAMA Netw Open. 2021;4(9):e2124721. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24721.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"590_CR199","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cncr.31741","volume":"125","author":"R Guo","year":"2019","unstructured":"Guo R, Tang LL, Mao YP, Du XJ, Chen L, Zhang ZC, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer. 2019;125(1):79\u201389. https:\/\/doi.org\/10.1002\/cncr.31741.","journal-title":"Cancer"},{"key":"590_CR200","doi-asserted-by":"publisher","unstructured":"Kim KY, Le QT, Yom SS, Pinsky BA, Bratman SV, Ng RH, et al. Current state of PCR-based Epstein-Barr virus DNA testing for nasopharyngeal cancer. J Natl Cancer Inst. 2017;109(4). https:\/\/doi.org\/10.1093\/jnci\/djx007.","DOI":"10.1093\/jnci\/djx007"},{"issue":"8","key":"590_CR201","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/1078-0432.Ccr-12-3702","volume":"19","author":"QT Le","year":"2013","unstructured":"Le QT, Zhang Q, Cao H, Cheng AJ, Pinsky BA, Hong RL, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19(8):2208\u201315. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-3702.","journal-title":"Clin Cancer Res"},{"key":"590_CR202","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","volume":"153","author":"AWM Lee","year":"2021","unstructured":"Lee AWM, Lee VHF, Ng WT, Strojan P, Saba NF, Rinaldo A, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer. 2021;153:109\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2021.05.022.","journal-title":"Eur J Cancer"},{"key":"590_CR203","doi-asserted-by":"publisher","first-page":"703995","DOI":"10.3389\/fonc.2021.703995","volume":"11","author":"CL Chiang","year":"2021","unstructured":"Chiang CL, Guo Q, Ng WT, Lin S, Ma TSW, Xu Z, et al. Prognostic factors for overall survival in nasopharyngeal cancer and implication for TNM staging by UICC: a systematic review of the literature. Front Oncol. 2021;11:703995. https:\/\/doi.org\/10.3389\/fonc.2021.703995.","journal-title":"Front Oncol"},{"issue":"3","key":"590_CR204","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annonc.2022.11.011","volume":"34","author":"P Bossi","year":"2023","unstructured":"Bossi P, Chan AT, Even C, Machiels JP. ESMO-EURACAN clinical practice guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease. Ann Oncol. 2023;34(3):247\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.011.","journal-title":"Ann Oncol"},{"issue":"1","key":"590_CR205","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijrobp.2010.09.011","volume":"82","author":"SF Su","year":"2012","unstructured":"Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys. 2012;82(1):327\u201333. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.09.011.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"590_CR206","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/jco.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol. 2021;39(7):840\u201359. https:\/\/doi.org\/10.1200\/jco.20.03237.","journal-title":"J Clin Oncol"},{"issue":"4","key":"590_CR207","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s12094-026-04252-5","volume":"28","author":"A Rueda Dom\u00ednguez","year":"2026","unstructured":"Rueda Dom\u00ednguez A, Cirauqui B, Garc\u00eda Casta\u00f1o A, Alvarez Cabellos R, Carral Maseda A, Castelo Fern\u00e1ndez B, et al. SEOM-TTCC clinical guideline for nasopharyngeal carcinoma (update 2025). Clin Transl Oncol. 2026;28(4):1151\u201364. https:\/\/doi.org\/10.1007\/s12094-026-04252-5.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"590_CR208","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ijrobp.2018.05.060","volume":"102","author":"LJ McDowell","year":"2018","unstructured":"McDowell LJ, Rock K, Xu W, Chan B, Waldron J, Lu L, et al. Long-term late toxicity, quality of life, and emotional distress in patients with nasopharyngeal carcinoma treated with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102(2):340\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.060.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"590_CR209","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fonc.2020.00930","volume":"10","author":"L McDowell","year":"2020","unstructured":"McDowell L, Corry J, Ringash J, Rischin D. Quality of life, toxicity and unmet needs in nasopharyngeal cancer survivors. Front Oncol. 2020;10:930. https:\/\/doi.org\/10.3389\/fonc.2020.00930.","journal-title":"Front Oncol"},{"issue":"8","key":"590_CR210","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/s1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J, Hu C, Xu M, Li W, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162\u201374. https:\/\/doi.org\/10.1016\/s1470-2045(21)00302-8.","journal-title":"Lancet Oncol"},{"issue":"6","key":"590_CR211","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41(6):1061-72.e4. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.014.","journal-title":"Cancer Cell"},{"issue":"4","key":"590_CR212","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaoncol.2023.6552","volume":"10","author":"J Dai","year":"2024","unstructured":"Dai J, Zhang B, Su Y, Pan Y, Ye Z, Cai R, et al. Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol. 2024;10(4):456\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6552.","journal-title":"JAMA Oncol"},{"issue":"9","key":"590_CR213","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamaoncol.2025.2191","volume":"11","author":"F Xue","year":"2025","unstructured":"Xue F, Ou D, Xie C, Lin S, Li J, Chen X, et al. Sequential vs induction plus concurrent chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol. 2025;11(9):1011\u201320. https:\/\/doi.org\/10.1001\/jamaoncol.2025.2191.","journal-title":"JAMA Oncol"},{"issue":"10445","key":"590_CR214","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/s0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403(10445):2720\u201331. https:\/\/doi.org\/10.1016\/s0140-6736(24)00594-4.","journal-title":"Lancet"},{"key":"590_CR215","doi-asserted-by":"publisher","first-page":"e085863","DOI":"10.1136\/bmj-2025-085863","volume":"392","author":"R You","year":"2026","unstructured":"You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, et al. Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial. BMJ. 2026;392:e085863. https:\/\/doi.org\/10.1136\/bmj-2025-085863.","journal-title":"BMJ"},{"issue":"1","key":"590_CR216","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4143\/crt.2021.101","volume":"54","author":"L Wang","year":"2022","unstructured":"Wang L, Miao J, Huang H, Chen B, Xiao X, Zhu M, et al. Long-term survivals, toxicities and the role of chemotherapy in early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy: a retrospective study with 15-year follow-up. Cancer Res Treat. 2022;54(1):118\u201329. https:\/\/doi.org\/10.4143\/crt.2021.101.","journal-title":"Cancer Res Treat"},{"issue":"8","key":"590_CR217","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jama.2022.13997","volume":"328","author":"LL Tang","year":"2022","unstructured":"Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, et al. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. JAMA. 2022;328(8):728\u201336. https:\/\/doi.org\/10.1001\/jama.2022.13997.","journal-title":"JAMA"},{"key":"590_CR218","doi-asserted-by":"publisher","first-page":"103652","DOI":"10.1016\/j.clon.2024.10.004","volume":"38","author":"H Zeng","year":"2025","unstructured":"Zeng H, Wang H, Liu S, Xu X. Concurrent chemoradiotherapy versus radiotherapy alone in the treatment of stage II and T3N0M0 nasopharyngeal carcinoma: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2025;38:103652. https:\/\/doi.org\/10.1016\/j.clon.2024.10.004.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"590_CR219","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ijc.32099","volume":"145","author":"WF Li","year":"2019","unstructured":"Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, et al. Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145(1):295\u2013305. https:\/\/doi.org\/10.1002\/ijc.32099.","journal-title":"Int J Cancer"},{"issue":"6","key":"590_CR220","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/s1470-2045(23)00163-8","volume":"24","author":"C Petit","year":"2023","unstructured":"Petit C, Lee A, Ma J, Lacas B, Ng WT, Chan ATC, et al. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol. 2023;24(6):611\u201323. https:\/\/doi.org\/10.1016\/s1470-2045(23)00163-8.","journal-title":"Lancet Oncol"},{"issue":"11","key":"590_CR221","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13(11):659\u201373. https:\/\/doi.org\/10.1038\/nrclinonc.2016.64.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10297","key":"590_CR222","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303\u201313. https:\/\/doi.org\/10.1016\/s0140-6736(21)01123-5.","journal-title":"Lancet"},{"issue":"8","key":"590_CR223","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell. 2024;42(8):1401-14.e4. https:\/\/doi.org\/10.1016\/j.ccell.2024.07.001.","journal-title":"Cancer Cell"},{"key":"590_CR224","doi-asserted-by":"publisher","unstructured":"Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018:Jco2018777847. https:\/\/doi.org\/10.1200\/jco.2018.77.7847.","DOI":"10.1200\/jco.2018.77.7847"},{"issue":"10380","key":"590_CR225","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/s0140-6736(23)00269-6","volume":"401","author":"R You","year":"2023","unstructured":"You R, Liu YP, Xie YL, Lin C, Duan CY, Chen DP, et al. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;401(10380):917\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(23)00269-6.","journal-title":"Lancet"},{"issue":"3","key":"590_CR226","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1001\/jamaoncol.2025.6245","volume":"12","author":"Y Huang","year":"2026","unstructured":"Huang Y, Sun D, Zhou H, Zhou T, Qu S, Li J, et al. Five-year outcome of camrelizumab plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a secondary analysis of the CAPTAIN-1st randomized clinical trial. JAMA Oncol. 2026;12(3):295\u2013302. https:\/\/doi.org\/10.1001\/jamaoncol.2025.6245.","journal-title":"JAMA Oncol"},{"issue":"4","key":"590_CR227","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2026.0020","volume":"12","author":"Y Yang","year":"2026","unstructured":"Yang Y, Yen CJ, Pan J, Wang H, Qu S, Chen N, et al. First-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer: three-year follow-up of the phase 3 RATIONALE-309 randomized clinical trial. JAMA Oncol. 2026;12(4):384\u201393. https:\/\/doi.org\/10.1001\/jamaoncol.2026.0020.","journal-title":"JAMA Oncol"},{"issue":"9","key":"590_CR228","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","volume":"6","author":"R You","year":"2020","unstructured":"You R, Liu YP, Huang PY, Zou X, Sun R, He YX, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1345\u201352. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1808.","journal-title":"JAMA Oncol"},{"key":"590_CR229","doi-asserted-by":"publisher","first-page":"110265","DOI":"10.1016\/j.radonc.2024.110265","volume":"196","author":"S Huang","year":"2024","unstructured":"Huang S, Jiang F, Cao C, Jin Q, Jin T, Hua Y, et al. Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: a prospective, single-arm, single-center clinical study. Radiother Oncol. 2024;196:110265. https:\/\/doi.org\/10.1016\/j.radonc.2024.110265.","journal-title":"Radiother Oncol"},{"issue":"1","key":"590_CR230","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"key":"590_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.06.003","author":"F Han","year":"2026","unstructured":"Han F, Xiang YQ, Wang XH, Qu S, Tang LQ, Shu XL, et al. Becotatug vedotin for recurrent\/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.06.003.","journal-title":"Ann Oncol"},{"issue":"4","key":"590_CR232","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-026-02290-5","volume":"86","author":"HA Blair","year":"2026","unstructured":"Blair HA. Becotatug vedotin: first approval. Drugs. 2026;86(4):573\u20139. https:\/\/doi.org\/10.1007\/s40265-026-02290-5.","journal-title":"Drugs"},{"issue":"6","key":"590_CR233","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, et al. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med. 2025;31(6):1949\u201357. https:\/\/doi.org\/10.1038\/s41591-025-03600-2.","journal-title":"Nat Med"},{"issue":"14","key":"590_CR234","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1200\/jco.22.01450","volume":"41","author":"X Ding","year":"2023","unstructured":"Ding X, Zhang WJ, You R, Zou X, Wang ZQ, Ouyang YF, et al. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study. J Clin Oncol. 2023;41(14):2571\u201382. https:\/\/doi.org\/10.1200\/jco.22.01450.","journal-title":"J Clin Oncol"},{"issue":"1","key":"590_CR235","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1038\/s41467-023-40402-x","volume":"14","author":"L Yuan","year":"2023","unstructured":"Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin DF, et al. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent\/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial. Nat Commun. 2023;14(1):4893. https:\/\/doi.org\/10.1038\/s41467-023-40402-x.","journal-title":"Nat Commun"},{"issue":"1","key":"590_CR236","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12916-023-03140-x","volume":"21","author":"Y Fang","year":"2023","unstructured":"Fang Y, Su N, Zou Q, Cao Y, Xia Y, Tang L, et al. Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. BMC Med. 2023;21(1):423. https:\/\/doi.org\/10.1186\/s12916-023-03140-x.","journal-title":"BMC Med"},{"issue":"12","key":"590_CR237","doi-asserted-by":"publisher","first-page":"101833","DOI":"10.1016\/j.xcrm.2024.101833","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zou Q, Zhao B, Su N, Li Z, Wang X, et al. Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm phase 2 trial (TORAL). Cell Rep Med. 2024;5(12):101833. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101833.","journal-title":"Cell Rep Med"},{"key":"590_CR238","doi-asserted-by":"publisher","first-page":"1250946","DOI":"10.3389\/fimmu.2023.1250946","volume":"14","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Xu M. EBV-induced T-cell responses in EBV-specific and nonspecific cancers. Front Immunol. 2023;14:1250946. https:\/\/doi.org\/10.3389\/fimmu.2023.1250946.","journal-title":"Front Immunol"},{"issue":"35","key":"590_CR239","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1200\/jco.2005.02.6195","volume":"23","author":"P Comoli","year":"2005","unstructured":"Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005;23(35):8942\u20139. https:\/\/doi.org\/10.1200\/jco.2005.02.6195.","journal-title":"J Clin Oncol"},{"issue":"9","key":"590_CR240","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","volume":"33","author":"CU Louis","year":"2010","unstructured":"Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33(9):983\u201390. https:\/\/doi.org\/10.1097\/CJI.0b013e3181f3cbf4.","journal-title":"J Immunother"},{"issue":"2","key":"590_CR241","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/annonc\/mdr134","volume":"23","author":"S Secondino","year":"2012","unstructured":"Secondino S, Zecca M, Licitra L, Gurrado A, Schiavetto I, Bossi P, et al. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol. 2012;23(2):435\u201341. https:\/\/doi.org\/10.1093\/annonc\/mdr134.","journal-title":"Ann Oncol"},{"issue":"12","key":"590_CR242","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.annonc.2024.08.2344","volume":"35","author":"HC Toh","year":"2024","unstructured":"Toh HC, Yang MH, Wang HM, Hsieh CY, Chitapanarux I, Ho KF, et al. Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024;35(12):1181\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2344.","journal-title":"Ann Oncol"},{"issue":"3","key":"590_CR243","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","volume":"37","author":"DT Harris","year":"2016","unstructured":"Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016;37(3):220\u201330. https:\/\/doi.org\/10.1016\/j.tips.2015.11.004.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"590_CR244","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.Can-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013;73(6):1676\u201388. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-2448.","journal-title":"Cancer Res"},{"issue":"19","key":"590_CR245","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.Ccr-14-1122-t","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, et al. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res. 2014;20(19):5009\u201322. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1122-t.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"590_CR246","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1007\/s12274-022-5254-x","volume":"16","author":"M Guo","year":"2023","unstructured":"Guo M, Duan X, Peng X, Jin Z, Huang H, Xiao W, et al. A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma. Nano Res. 2023;16(4):5357\u201367. https:\/\/doi.org\/10.1007\/s12274-022-5254-x.","journal-title":"Nano Res"},{"issue":"1","key":"590_CR247","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12951-023-02069-w","volume":"21","author":"Y Xiang","year":"2023","unstructured":"Xiang Y, Tian M, Huang J, Li Y, Li G, Li X, et al. LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion. J Nanobiotechnology. 2023;21(1):324. https:\/\/doi.org\/10.1186\/s12951-023-02069-w.","journal-title":"J Nanobiotechnology"},{"issue":"8","key":"590_CR248","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41419-021-04042-7","volume":"12","author":"F Luo","year":"2021","unstructured":"Luo F, Lu FT, Qiu MZ, Zhou T, Ma WJ, Luo M, et al. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2\/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2\/STAT3\/MCL-1 signaling pathway. Cell Death Dis. 2021;12(8):772. https:\/\/doi.org\/10.1038\/s41419-021-04042-7.","journal-title":"Cell Death Dis"},{"issue":"7","key":"590_CR249","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41419-018-0789-1","volume":"9","author":"N Li","year":"2018","unstructured":"Li N, Yang L, Qi XK, Lin YX, Xie X, He GP, et al. BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc. Cell Death Dis. 2018;9(7):761. https:\/\/doi.org\/10.1038\/s41419-018-0789-1.","journal-title":"Cell Death Dis"},{"issue":"9","key":"590_CR250","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1021\/acs.molpharmaceut.3c00491","volume":"20","author":"Q Yang","year":"2023","unstructured":"Yang Q, Guo Y, Zhou Y, Song J, Song Y, Li H, et al. Multifunctional nanotheranostics for dual-modal imaging-guided precision therapy of nasopharyngeal carcinoma. Mol Pharm. 2023;20(9):4743\u201357. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00491.","journal-title":"Mol Pharm"},{"key":"590_CR251","doi-asserted-by":"publisher","first-page":"113909","DOI":"10.1016\/j.colsurfb.2024.113909","volume":"238","author":"S Sun","year":"2024","unstructured":"Sun S, Han R, Sun Y, Chen W, Zhao L, Guan X, et al. A minimalist cancer cell membrane-shielded biomimetic nanoparticle for nasopharyngeal carcinoma active-targeting therapy. Colloids Surf B Biointerfaces. 2024;238:113909. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.113909.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"590_CR252","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.2147\/ijn.S357493","volume":"17","author":"Y Lin","year":"2022","unstructured":"Lin Y, Qiu T, Lan Y, Li Z, Wang X, Zhou M, et al. Multi-modal optical imaging and combined phototherapy of nasopharyngeal carcinoma based on a nanoplatform. Int J Nanomedicine. 2022;17:2435\u201346. https:\/\/doi.org\/10.2147\/ijn.S357493.","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"590_CR253","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.radonc.2013.10.020","volume":"110","author":"X Sun","year":"2014","unstructured":"Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398\u2013403. https:\/\/doi.org\/10.1016\/j.radonc.2013.10.020.","journal-title":"Radiother Oncol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00590-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00590-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00590-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:46:18Z","timestamp":1789616778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00590-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":253,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00590-6","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"175"}}